Tony's Diary Package — page 714

1/NIAID) [E] gov>; Erbelding, Emily vholley@fnih.org>; Menetski, dur View Please see e-mail below from Dr. Venkatachalam to Francis Collins. Although this is still at the level of anecdote, I am hearing from people who are doing studies in vitro that the B.1.617 variant is at least as concerning as the B.1.351. We should discuss this at our next meeting. Best, Tony Anthony S. Fauci, MD Director National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: (301) 496-2263 FAX: (301) 496-4409 E-mail: afauci@niaid.nih.gov The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives. From: Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov> Sent: Thursday, April 29, 2021 5:56 AM To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>; Lane, Cliff (NIH/NIAID) [E] <clane@niaid.nih.gov>; Mascola, John (NIH/VRC) [E] <jmascola@mail.nih.gov>; Erbelding, Emily (NIH/NIAID) [E] <emily.erbelding@nih.gov>; Wholley, David (FNIH) [T] <dwholley@fnih.org>; Menetski, Joseph (FNIH) [T] <jmenetski@fnih.org> Subject: FW: Concerning news about the B.1.617 variant from India and your view More concerns about B.1.617 and the effectiveness of vaccines. From: Venkatachalam, Sundar (NIH/NCI) [E] <sundar.venkatachalam@nih.gov> Sent: Thursday, April 29, 2021 4:53 AM To: Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov> Subject: Concerning news about the B.1.617 variant from India and your view